Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases

International Journal of Colorectal Disease

Volumn 29, Issue 9, 2014, Pages 1081-1089

  Sammartino, P ^a   Sibio, S ^a   Biacchi, D ^a   Cardi, M ^a   Mingazzini, P ^a   Rosati, M S ^a   Cornali, T ^a   Sollazzo, B ^a   Atta, J Maherfouad ^a   Di Giorgio, A ^a  

^a POLICLINICO UMBERTO I   (Italy)

Author keywords

Advanced colorectal cancer; Peritoneal spread; Prevention of peritoneal carcinomatosis; Proactive management

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CHOLECYSTECTOMY; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HEMICOLECTOMY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; HYSTERECTOMY; KAPLAN MEIER METHOD; LOCAL RECURRENCE FREE SURVIVAL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIMODALITY CANCER THERAPY; OMENTECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNET RING CARCINOMA; SMALL INTESTINE RESECTION; SURGICAL APPROACH; ADJUVANT CHEMOTHERAPY; CASE CONTROL STUDY; COLONIC NEOPLASMS; FOLLOW UP; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84906307464     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-014-1929-4     Document Type: Article

References (37)

1. Glehen O, Kwiatkowski F, Sugarbaker PH et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22(16):3284-3292 (Pubitemid 41103684)
2. Esquivel J, Elias D, Baratti D et al (2008) Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol 98(4):263-267
3. Elias D, Gilly F, Boutitie F et al (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28(1):63-68
4. Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH editor; Peritoneal carcinomatosis: principles of management. Boston Kluwers Academic 359-74
5. Koh JL, Yan TD, Glenn D et al (2009) Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol 16(2):327-333
6. Elias D, Honore C, Dumont F et al (2011) Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 254(2):289-293
7. Honoré C, Goéré D, Souadka A et al (2013) Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol 20(1):183-192
8. Nitsche U, Rosenberg R, Balmert A et al (2012) Integrative marker analysis allows risk assessment formetastasis in stage II colon cancer. Ann Surg 256(5):763-771
9. Sugarbaker PH, Sammartino P, Tentes AA (2012) Proactive management of peritoneal metastases from colorectal cancer: the next logical step toward optimal locoregional control. Colorect Cancer 1:115-123
10. Sugarbaker PH (2013) The evolution of treatment for peritoneal metastases. Colorect Cancer 2:189-192
11. Sammartino P, Sibio S, Biacchi D, et al (2012) Prevention of peritoneal metastases from colon cancer in high-risk patients: preliminary results of surgery plus prophylactic HIPEC. Gastroenterol Res Pract.2012
12. Symonds DA, Vickery AL (1976) Mucinous carcinoma of the colon and rectum. Cancer 37(4):1891-1900
13. Ogino S, Brahmandam M, Cantor M et al (2006) Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 19(1):59-68 (Pubitemid 43250979)
14. Mekenkamp LJM, Heesterbeek CJ, Punt CJA et al (2012) Reply letter to: Signet ring cell carcinoma as a potential confounding factor in the analysis of outcomes with colorectal mucinous adenocarcinoma. Eur J Cancer 48:3128-3129
15. World Health Organization (1979) WHO handbook for reporting results of cancer treatment. WHO, Geneva, Switzerland
16. Nelson H, Petrelli N, Carlin A et al (2001) Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 18;93(8):583-596
17. Saxena A, Yan TD, Morris DL (2010) A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World J Surg 34(1):70-78
18. Iafrate F, Ciolina M, Sammartino P et al (2012) Peritoneal carcinomatosis: imaging with 64-MDCT and 3 T MRI with diffusionweighted imaging. Abdom Imaging 37(4):616-627
19. Catenacci DV, Kozloff M, Kindler HL et al (2011) Personalized colon cancer care in 2010. Semin Oncol 38(2):284-308
20. Jayne DG, Fook S, Loi C et al (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89(12):1545-1550 (Pubitemid 35404323)
21. Elias D, Lefevre JH, Chevalier J et al (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clinical Oncol 27(5):681-685
22. Kerscher AG, Chua TC, Gasser M et al (2013) Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer 108(7):1432-1439
23. Noura S, Ohue M, Shingai T et al (2011) Effects of intraperitoneal chemotherapy with mitomycin C on the prevention of peritoneal recurrence in colorectal cancer patients with positive peritoneal lavage cytology findings. Ann Surg Oncol 18(2):396-404
24. Hompes D, Tiek J, Wolthuis A et al (2012) HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome? Ann Oncol 23(12):3123-3129
25. Rottoli M, Stocchi L, Dietz DW (2012) T4N0 colon cancer has oncologic outcomes comparable to stage III in a specialized center. Ann Surg Oncol 19(8):2500-2505
26. Stewart C, Hillery S, Havlat M (2006) Serosal involvement in colorectal carcinoma. Histopathology 49(4):435-437
27. Kojima M, Nakajima K, Ishii G et al (2010) Peritoneal elastic laminal invasion of colorectal cancer: the diagnostic utility and clinicopathologic relationship. Am J Surg Pathol 34(9):1351-1360
28. Winder T, Lenz HJ (2010) Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy. Oncologist 15(8):836-844
29. Song W, Wu SJ, He YL et al (2009) Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring cell or nonmucinous adenocarcinoma: experience at an institution in southern China. Chin Med J 122(13):1486-1491
30. Lemmens VE, Klaver YL, Verwaal VJ et al (2011) Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 128(11):2717-2725
31. Numata M, Shiozawa M, Watanabe T et al (2012) The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease. World J Surg Oncol 10:109
32. Sugarbaker PH (2001)Mucinous colorectal carcinoma. J Surg Oncol 77(4):282-283
33. Catalano V, Loupakis F, Graziano F et al (2009) Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer 100(6):881-887
34. Lee DW, Han SW, Lee HJ et al (2013) Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy. Br J Cancer 108(10):1978-1984
35. Elias D, Goéré D, Dumont F et al (2014) Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer 50(2):332-340
36. Sammartino P, Sibio S, Accarpio F, et al (2014) Prevention of peritoneal carcinomatosis from colorectal cancer: a critical issue. Ann Surg Mar;259 (3)
37. Sugarbaker PH (2000) It's what the surgeon doesn't see that kills the patient. J Nippon Med Sch 67(1):5-8